Several studies have shown that adenosine suppresses CD8+ T-cells by activating the adenosine A2A receptor (A2AR) and blocking A2AR with selective antagonists results in enhanced anti-cancer immune responses (4, 7–9). This evidence concerns the gene CD8A and cancer.